Recent publication with MetwareBio's services

MetwareBio isn't just a leading CRO in metabolomics – we're a dedicated partner, fueling groundbreaking research across medical science, agriculture, and beyond. In 2023, we collaborated with over 300 research teams globally, contributing crucial insights to diverse areas including colorectal cancer, inflammatory bowel disease, and sustainable plant breeding.

Colorectal cancer 

1. Wang, Ling et al. "Male-Biased Gut Microbiome and Metabolites Aggravate Colorectal Cancer Development." Advanced science (Weinheim, Baden-Wurttemberg, Germany) vol. 10,25 (2023): e2206238. doi:10.1002/advs.202206238

The authors used TM Widely-Targeted Metabolomics to investigate the potential causes of sexual dimorphism in CRC from the perspective of sex-biased gut microbiota and metabolites. The results showed that sexual dimorphism in colorectal tumorigenesis is observed in both ApcMin/+ mice and azoxymethane (AOM)/dextran sulfate sodium (DSS)-treated mice with male mice have significantly larger and more tumors, accompanied by more impaired gut barrier function. In conclusion, the sex-biased gut microbiome and metabolites contribute to sexual dimorphism in CRC.  Modulating sex-biased gut microbiota and metabolites could be a potential sex-targeting therapeutic strategy for CRC.

2. Wang, Chenran et al. "ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy." Nature metabolism vol. 5,10 (2023): 1765-1786. doi:10.1038/s42255-023-00883-y

The authors used Energy Targeted Metabolomics to explore the molecular mechanisms of metabolic reprogramming regulating resistance to antiangiogenic therapy in cancer. They identify the glycolytic enzyme enolase 2 (ENO2) as a driver of resistance to antiangiogenic therapy in colorectal cancer (CRC) mouse models and human participants. The findings reveal that ENO2 constitutes a useful predictive biomarker and therapeutic target for resistance to antiangiogenic therapy in CRC, and uncover a previously undefined and metabolism-independent role of PEP in regulating resistance to antiangiogenic therapy by functioning as an endogenous HDAC1 inhibitor.

Partnering for Success

These are just a glimpse into the diverse research landscapes where MetWareBio's expertise unlocks valuable insights. By combining innovative metabolomics, lipidomics ,and multiomics solutions with expert collaboration, we empower researchers to break new ground in medicine, agriculture, and beyond.

Ready to delve deeper into the mysteries of metabolism? Contact us today and let's embark on a collaborative journey of discovery.